Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05977621 · ClinicalTrials.gov registry record
Trans-Rectal Ultrasound of the Female Pelvis for Real-Time MRI-US Fusion Based Needle Tracking
A clinical trial of Uterine Cancer, sponsored by Duke University.
- Recruiting
- Registry status
- 17
- Enrollment target
- 1
- Study location
NCT05977621: Recruiting study of Uterine Cancer, sponsored by Duke University.
NCT05977621 is a study of Uterine Cancer that is actively recruiting participants, run by Duke University. The registered enrollment target is 17 participants, below the 271-participant average among 27 other Uterine Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05977621, a study of Uterine Cancer, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to utilize transrectal ultrasound (TRUS) images of the intact and post-hysterectomy female pelvis in order to provide feasibility information for a Magnetic Resonance Imaging (MRI)-TRUS fusion based 3D needle navigation system for use in image guided brachytherapy. The fusion and needle guidance will be performed using Eigen Health's navigation system that currently provides targeted MR/Ultrasound fusion based prostate biopsies utilizing a proprietary 3D semi-robotic navigation system.
Conditions Studied
Interventions
- OTHER Transrectal ultrasound (TRUS)
Study Locations (1)
North Carolina
- Duke Cancer Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2024-02-07 |
| Est. Completion | 2027-03 |
What NCT05977621 shows while recruiting
NCT05977621 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 271-participant average among 27 other Uterine Cancer trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Uterine Cancer appearing as the primary indexed condition, and to 1 intervention - of which Transrectal ultrasound (TRUS) is the first listed.
NCT05977621 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05977621 about?
NCT05977621 is a clinical study titled "Trans-Rectal Ultrasound of the Female Pelvis for Real-Time MRI-US Fusion Based Needle Tracking". The purpose of this study is to utilize transrectal ultrasound (TRUS) images of the intact and post-hysterectomy female pelvis in order to provide feasibility information for a Magnetic Resonance Imaging (MRI)-TRUS fusion based 3D needle navigation system for use in image guided brachytherapy. The f...
What is the current status of trial NCT05977621?
This trial is currently recruiting. The enrollment target is 17 participants. The study started on 2024-02-07. Estimated completion is 2027-03.
What conditions does trial NCT05977621 study?
This clinical trial studies the following conditions: Uterine Cancer.
What interventions are being tested in trial NCT05977621?
The interventions under investigation include: Transrectal ultrasound (TRUS) (OTHER).
Who is sponsoring clinical trial NCT05977621?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05977621 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uterine Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05977621's enrollment target sits among peer trials
17 24th of 27 higher than 4 of 27 other Uterine Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Uterine Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
RECRUITING · Phase 2
-
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
RECRUITING · NA
-
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
RECRUITING · Phase 1
-
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
RECRUITING · Phase 1
-
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
RECRUITING · Phase 2
-
Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI